Vifor

IFBC supports Vifor Pharma Group in the annual impairment process with an update of the cost of capital to be applied. The update is based on a cost of capital concept developed for Vifor Pharma, in which the calculation principles for the individual parameters and the handling of different currencies were defined as basis for the goodwill impairment testing. The Vifor Pharma Group is a global specialty-pharmaceutical company headquartered in Switzerland. The company’s goal is to become a global leader in iron deficiency, nephrology and cardiorenal therapies.